|
||||||
 |
||||||
|
|
|
 |
|
          August 25, 2010
August 20, 2010
|
|
All prices delayed at least 15 minutes. |
|
Corporate News ReleaseBioniche Granted Additional Patent for Mycobacterial Cell Wall Technology
17/05/05 Belleville, ON, May 17, 2005 – Bioniche Life Sciences Inc. (TSX:BNC), a research-based, technology-driven human and animal health biopharmaceutical company, today announced that it has had a new patent issued by the United States Patent and Trademark Office (USPTO) on its core mycobacterial cell wall technology. The new patent relates to the Company’s proprietary composition, Mycobacterial Cell Wall-DNA Complex (MCC), which has been shown to possess immunomodulatory, vaccine adjuvant, and chemotherapeutic activities. The new patent is:
“This patent provides protection for the use of mycobacterial cell wall-DNA complexes as anti-inflammatory agents,” noted Dr. Nigel C. Phillips, Chief Scientific Officer at Bioniche Life Sciences Inc. and patent co-inventor. “The application fields for this aspect of our core mycobacterial cell wall technology are the treatment of inflammation in general, as well specific uses in immune-mediated inflammation, osteoarthritis, rheumatoid arthritis, glomerulonephritis, colitis, and cystitis. This technology platform already comprises the use of mycobacterial cell wall-DNA complexes as immunomodulators, vaccine adjuvants, anticancer therapeutic agents, and complements other technology platforms within the Company that are either commercialized or under development.” Dr. Mario C. Filion, Head of Biomedical Research at Bioniche Life Sciences and patent co-inventor added, “This U.S. patent will provide us protection for the use of mycobacterial cell wall-DNA complexes for reducing inflammation in both animals and humans.” Graeme McRae, President & CEO of Bioniche Life Sciences Inc., stated, “We continue to discover and safeguard versatile applications for our MCC technology. The extensive intellectual property portfolio on MCC enables us to capitalize on multiple market opportunities and provide greater potential return on our research and development investment.”
About the Mycobacterial Cell Wall Technology PlatformBioniche’s core mycobacterial cell wall technology platform comprises compositions with antiviral, immune adjuvant, immune stimulatory, and anti-inflammatory activity, as well as chemotherapeutic activity against cancer cells. A number of compositions are commercialized for use in veterinary applications, and the company is actively developing compositions for use in a number of human applications. In human health, MCC is being targeted for the treatment of bladder cancer initially, with a Phase III clinical trial planned in North America and Europe. ###
|
|
Categories:
|
Copyright 2004, Bioniche Life Sciences Inc. All rights reserved | Legal Disclaimer | Privacy Policy